National
U.S. commission considers ways to stop anti-gay Uganda bill
U.S. Rep. Tammy Baldwin (D-Wis.) (DC Agenda photo by Michael Key)
Greater involvement from first lady Michelle Obama was one option discussed during a recent congressional hearing as a way for the U.S. to help derail a harshly anti-gay bill in Uganda from becoming law.
Cary Alan Johnson, executive director of the International Gay & Lesbian Human Rights Commission, was among the people who testified before the Tom Lantos Human Rights Commission on Thursday that Obama’s work against the international HIV/AIDS epidemic would make her a strong voice against the bill.
Johnson said the women’s caucus in the Ugandan parliament is supporting the legislation and opposition from the first lady — as well as President Obama — could influence women’s groups in Uganda to drop their support.
“I’m wondering if there is women leaders within the U.S. Congress — and perhaps the first lady herself — might be able to play some role in having discussions about the potential impact of this bill — not just on human rights, but on HIV prevention within the country,” Johnson said.
Julius Kaggwa, a leader of the Civil Society Coalition on Human Rights & Constitutional Law who came from Uganda to testify on the legislation, also said greater involvement from President Obama and Michelle Obama would be helpful in efforts to stop the bill.
“If President Obama and the first lady of the United States can engage more with our first family — especially in the area of HIV/AIDS, which is of great concern to us as sexual minorities — and the issue of human rights generally, I think that would be very, very helpful,” he said.
A stronger voice from the first lady and President Obama was one among several options considered to stop the anti-gay legislation that’s been pending the Uganda parliament since October.
Homosexual acts are already illegal in Uganda, but the bill would, among other things, institute the death penalty for repeat offenders of the homosexual acts ban and for those who have homosexual sex while HIV positive. The harsh penalties for LGBT people in the legislation have inspired growing outrage and concern around the world, including LGBT activists in the U.S.
Karl Wycoff, deputy assistant secretary of state for East African Affairs (DC Agenda photo by Michael Key)
Karl Wycoff, deputy assistant secretary of state for East African Affairs, testified that the State Department has been working to prevent the bill from being enacted into law even as the U.S. considers the country an ally.
“The introduction of this anti-homosexuality bill in Uganda characterizes just such a moment — one where we must say to our friends who’s friendship we value that together we must stand against injustice, and in this case, injustice against the LGBT community,” he said.
Wycoff noted how the White House in January issued a statement in opposition to the legislation and said Secretary of State Hillary Clinton has expressed concerns about the bill with Ugandan President Yoweri Museveni in addition to publicly opposing the legislation in two speeches.
“Our embassy … has been very active on this subject with representatives of the Ugandan government, with civil society, with local gay and lesbian groups and with others who press for this bill to be dropped,” Wycoff said.
Last month, DC Agenda first reported State Department officials had received assurances from Museveni that he would work to block the legislation from becoming law and would veto the bill should it come to his desk. But during the hearing, Wycoff declined to characterize publicly the discussions the State Department had with the president.
Witnesses also discussed efforts of activists within Uganda working to prevent the bill from becoming law. Kaggwa said local groups have been trying to stop the measure, but noted that persuading lawmakers to oppose the bill is difficult because of the country’s deep cultural beliefs against homosexuality.
Kaggwa said one of the best points for opponents to bring up about the legislation is how it would require Ugandan citizens to report on those believed to be homosexual.
“The element of setting a mother against a daughter, the element of setting a sister against a brother, is something that we all can identify with,” Kaggwa said. “These are the arguments that we are using. We should make this bill really draconian, that instead of bringing together families, instead of preserving family, as purported by people who are pushing the bill, it’s [separating] families.”
Following the testimony, lesbian Rep. Tammy Baldwin (D-Wis.), who chaired the hearing, told reporters that bolstering the local effort in Uganda against the legislation would be one means for the United States to step up efforts against the bill.
“I do think it is important for us to listen and receive guidance from people on the ground in Uganda — not just thinking from afar what to do,” she said. “I think there’s probably additional ways where we can empower local activists, local voices in Uganda at the same time as we speak crystal clear our dedication to human rights for all [people] across the globe.”
Another option lawmakers are considering is revoking Uganda’s beneficiary trade status should the bill become law. Baldwin noted during the hearing that earlier this month, Sen. Ron Wyden (D-Ore.) sent a letter to Clinton saying Uganda’s trade relationship with the United States would be revoked if the country’s parliament enacts the legislation.
While a number of strategies were put forth as ways to prevent the legislation from becoming law, one option witnesses denied as being an appropriate response was restriction of funds under the President’s Emergency Plan for AIDS Relief. The program, also known as PEPFAR, is a multi-billion dollar initiative started by former President George W. Bush that provides treatment for people living with HIV/AIDS in developing countries.
Christine Lubinski, executive director of the HIV Medicine Association, said the $1.3 billion that the U.S. spends in aid to Uganda is “too much of a day-to-day lifeline for too many people.”
“It seems like there’s significant other avenues to pursue; the HIV money would not be good one,” she said.
But Johnson said there could be other avenues to pursue with AIDS relief money if Uganda passes the legislation. He said PEPFAR money could be “channeled differently” to non-governmental organizations that would implement HIV/AIDS relief programs in the country.
Another concern raised during the hearing was whether international efforts would have an adverse effect on stopping the anti-gay legislation because of the country’s history under colonial rule.
Wycoff said attention from the international community has actually contributed to some efforts in Uganda calling for the passage of the legislation.
“Ironically, foreign criticism of the bill has in some ways bolstered internal support for the legislation as many Ugandans interpret foreign condemnation as interference in their internal affairs,” he said.
But Kaggwa said international concern about the legislation is helpful, so long as local opposition against the bill is heard just as strongly.
Julius Kaggwa, a leader of the Civil Society Coalition on Human Rights & Constitutional Law (DC Agenda photo by Michael Key)
“It is important that these local, indigenous voices are heard as heavily or as loudly as the international voices,” he said. “We believe that if that voice supplements our own voices, then we will be productive. But if the foreign voices are louder than ours, then I’m afraid that might have a counter-productive effect.”
Johnson said people opposed to the legislation are working to make sure both local and regional voices are heard against the bill, and that Obama could make the local voices stronger.
“I think that could be an aspect in which the administration could be more proactive in terms of talking to other African nations, and talking to the African Union, about making its voice heard on the legislation,” he said.
A number of Democratic U.S. House members spoke out against the bill during the hearing. Rep. Jim McGovern (D-Mass.), co-chairman of the commission, said the bill “is steeped in religious bigotry and homophobia.”
“I want to make it clear that there are many members in this Congress — both Democrat and Republican — who have deep, deep concerns about what’s happening in Uganda and are outraged by this draft legislation,” he said.
Baldwin called the legislation “an extreme and hateful attempt to make people criminals not because of anything they do, but because of who they are and who they love.”
She noted that 90 other U.S. House members joined her in signing a letter to presidents Obama and Museveni, requesting their strong opposition to the legislation.
“I hope that all Ugandans, and particularly those who are [LGBT], will hear the voice of this Congress state very clearly that we will not tolerate these types of human rights violations,” she said.
No Republican member of the commission attended the hearing. A Republican staffer for the commission didn’t immediately respond to DC Agenda’s request to comment on why GOP members were absent.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
The White House
EXCLUSIVE: Democracy Forward files FOIA lawsuit after HHS deadnames Rachel Levine
Trans former assistant health secretary’s name changed on official portrait
Democracy Forward, a national legal organization that works to advance democracy and social progress through litigation, policy and public education, and regulatory engagement, filed a lawsuit Friday in federal court seeking to compel the U.S. Department of Health and Human Services to release information related to the alteration of former Assistant Secretary for Health Adm. Rachel Levine’s official portrait caption.
The lawsuit comes in response to the slow pace of HHS’s handling of multiple Freedom of Information Act requests — requests that federal law requires agencies to respond to within 20 working days. While responses can take longer due to backlogs, high request volumes, or the need for extensive searches or consultations, Democracy Forward says HHS has failed to provide any substantive response.
Democracy Forward’s four unanswered FOIA requests, and the subsequent lawsuit against HHS, come days after someone in the Trump-Vance administration changed Levine’s official portrait in the Hubert H. Humphrey Building to display her deadname — the name she used before transitioning and has not used since 2011.
According to Democracy Forward, HHS “refused to release any records related to its morally wrong and offensive effort to alter former Assistant Secretary for Health Admiral Rachel Levine’s official portrait caption.” Levine was the highest-ranking openly transgender government official in U.S. history and served as assistant secretary for health and as an admiral in the U.S. Public Health Service Commissioned Corps from 2021 to 2025.
Democracy Forward President Skye Perryman spoke about the need to hold the Trump-Vance administration accountable for every official action, especially those that harm some of the most targeted Americans, including trans people.
“The question every American should be asking remains: what is the Trump-Vance administration hiding? For an administration that touts its anti-transgender animus and behavior so publicly, its stonewalling and silence when it comes to the people’s right to see public records about who was behind this decision is deafening,” Perryman said.
“The government’s obligation of transparency doesn’t disappear because the information sought relates to a trailblazing former federal official who is transgender. It’s not complicated — the public is entitled to know who is making decisions — especially decisions that seek to alter facts and reality, erase the identity of a person, and affect the nation’s commitment to civil rights and human dignity.”
“HHS’s refusal to respond to these lawful requests raises more serious concerns about transparency and accountability,” Perryman added. “The public has every right to demand answers — to know who is behind this hateful act — and we are going to court to get them.”
The lawsuit also raises questions about whether the alteration violated federal accuracy and privacy requirements governing Levine’s name, and whether the agency improperly classified the change as an “excepted activity” during a lapse in appropriations. By failing to make any determination or produce any records, Democracy Forward argues, HHS has violated its obligations under federal law.
The case, Democracy Forward Foundation v. U.S. Department of Health and Human Services, was filed in the U.S. District Court for the District of Columbia. The legal team includes Anisha Hindocha, Daniel McGrath, and Robin Thurston.
The Washington Blade reached out to HHS, but has not received any comment.
The lawsuit and four FOIA requests are below:
Rush reopens after renewing suspended liquor license
Few transgender people benefit from India’s low-income housing program
Exciting electrics: Hyundai Ioniq 5, Volkswagen ID.4
Child- and pet-proofing your home for the holidays
‘Dogs of Venice’ looks at love lost and rediscovered
LGBTQ Democrats say they’re ready to fight to win in 2026
Brian Footer suspends campaign for Ward 1 D.C. Council seat
Lighting candles in a time of exhaustion
2026 elections will bring major changes to D.C. government
Kazakh Senate approves anti-LGBTQ propaganda bill
-
Politics5 days agoLGBTQ Democrats say they’re ready to fight to win in 2026
-
District of Columbia5 days ago
Brian Footer suspends campaign for Ward 1 D.C. Council seat
-
Opinions5 days ago
Lighting candles in a time of exhaustion
-
Opinions4 days ago
2026 elections will bring major changes to D.C. government
